Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Neurosci Res. 2019 Jul 11;155:56–62. doi: 10.1016/j.neures.2019.07.003

Figure 3. Repeated MDPV exposure produces deficit in NOR that is prevented by a D1 receptor antagonist.

Figure 3.

(A) Rats were treated with MDPV (1 mg/kg) or saline 3x/day for 10 days. Rats from both treatment groups were pretreated with a D1 antagonist (SCH 23390) (0.3 mg/kg), D2 antagonist (eticlopride) (0.1 mg/kg), or saline 30 min before the first daily injections of MDPV. Data are presented as discrimination index + S.E.M., N=8 rats/group. **p < 0.05 versus SAL + MDPV group. (Insert) Rats injected once with MDPV (1 mg/kg) or saline were tested for NOR. N=4–6 rats/group.